Eli Lilly has entered into a collaboration with Hong Kong-based biotech Insilico Medicine focused on AI-driven drug discovery across multiple therapeutic areas. The deal could potentially generate more than $2 billion for Insilico Medicine as Lilly works to sustain its industry-leading position.
The partnership leverages Insilico's artificial intelligence platform for drug discovery and development, though specific therapeutic targets and timelines were not disclosed in the announcement. The collaboration represents Lilly's continued commitment to expanding its AI capabilities in pharmaceutical research.